Antiviral therapy is a critical opportunity within Healthcare for use of the TPR4000™. The current COVID-19 health and socioeconomic crisis has created a global response that is moving Symbios to reprioritize application of its patented technology. The company is actively engaging with partners and the NSF to test the TPR4000 and its ability to deliver aqueous plasma therapeutics to treat patients that have contracted COVID-19. Testing is designed to prove its efficacy deactivating the virus as has been demonstrated with pancreatic cancer cells and legionella and other bacteria.
The TPR4000 aqueous plasma therapeutics also represents a critical solution to overcoming treatment issues that currently plague viral therapies including toxicity and drug resistance. They also may improve the efficacy of approved anti-viral drugs which should allow for rapid FDA approval for use in humans. Symbios has been approved to submit a proposal to the NSF rapid approval program for COVID-19 therapies.